<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00755456</url>
  </required_header>
  <id_info>
    <org_study_id>IP-002-05</org_study_id>
    <nct_id>NCT00755456</nct_id>
  </id_info>
  <brief_title>Effect of an L-carnitine-containing Peritoneal Dialysis (PD) Solution on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD)</brief_title>
  <official_title>Phase 2 Study of the Effect of a Peritoneal Dialysis Solution Containing Glucose (1.5%) and L-carnitine (0.1%) on Insulin Sensitivity in Patients on Continuous Ambulatory Peritoneal Dialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iperboreal Pharma Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iperboreal Pharma Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is initiated in order to assess the impact of a PD solution containing
      L-carnitine on insulin sensitivity measured by a hyperinsulinemic euglycemic clamp.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on insulin sensitivity evaluated by euglycemic hyperinsulinemic clamp</measure>
    <time_frame>time 0, 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on plasma lipids and lipoprotein profile</measure>
    <time_frame>-2 weeks, time 0, 1 month, 2 months, 3 months, 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the efficacy of L-Carnitine containing PD solution on hematological parameters (hemoglobin and EPO requirements)</measure>
    <time_frame>-2 weeks, time 0, 2 months, 4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD solution</intervention_name>
    <description>Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD solution containing L-carnitine</intervention_name>
    <description>Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥18 years

          2. Have a diagnosis of ESRD and have been on Continuous Ambulatory Peritoneal Dialysis
             (CAPD) for at least 3 months

          3. Be in a stable clinical condition during the four weeks immediately prior to Screening
             Period as demonstrated by medical history, physical examination and laboratory testing

          4. Have a blood hemoglobin concentration above 8,5 g/100ml (data will be verified with
             Investigators)

          5. Have not experienced peritonitis episodes in the last 3 months

          6. Be treated with Extraneal (nocturnal exchange bag solution) for at least 1 month

          7. Be treated with 3 diurnal exchange bag solutions (1.5% or 2.5% glucose) and one
             nocturnal exchange bag solution (Extraneal)

          8. Have Kt/V urea measurement &gt; 1.7 per week in a previous test performed within 6 months
             that should be confirmed at Baseline Visit

          9. Have a minimum weekly creatinine clearance of 45 litres in a previous test performed
             within 6 months that should be confirmed at Baseline Visit

         10. Have a D/P Creatinine ratio at Peritoneal Equilibration Test (PET) between 0.50 and
             0.81 in a previous test performed within 6 months that should be confirmed at Baseline
             Visit

         11. Have a D/P Glucose ratio at Peritoneal Equilibration Test (PET) between 0.26 and 0.49
             in a previous test performed within 6 months that should be confirmed at Baseline
             Visit

         12. Be treated by the participating clinical Investigator for a period of at least three
             months

         13. Have understood and signed the Informed Consent Form.

        Exclusion Criteria:

          1. Have a history of drug or alcohol abuse in the six months prior to entering the
             protocol

          2. Be in treatment with androgens

          3. Have Diabetes Mellitus (as defined by the American Diabetes Society, objectively
             documented by a fasting plasma glucose and HbA1c determinations)

          4. Have clinically significant abnormal liver function test (SGOT, SGPT, and gamma-GT &gt; 2
             times the upper normal limit)

          5. Have acute infectious conditions (i.e.: pulmonary infection, acute hepatitis, high or
             low urinary tract infections, renal parenchymal infection, pericarditis, etc)

          6. Have a history of congestive heart failure and clinically significant arrhythmia

          7. Have an history of epilepsy or any NCS disease

          8. Have malignancy within the past 5 years, including lymphoproliferative disorders

          9. Have any medical condition that, in the judgment of the Investigator, would jeopardize
             the patient's safety following exposure to study drug, particularly if patient's life
             expectancy is less than 1 year

         10. Have a history of L-Carnitine therapy or use in the month prior to entering the
             protocol

         11. Have used any investigational drug in the 3 months prior to entering the protocol

         12. Be in pregnancy, lactation, fertility age without protection against pregnancy by
             adequate contraceptive means
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Bonomini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G. d'Annunzio University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arduino Arduini, MD</last_name>
    <role>Study Director</role>
    <affiliation>Iperboreal Pharma Srl</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi Godi, MD</last_name>
    <phone>+39 06 79312131</phone>
    <email>lgodi@harrison-cro.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renal and Dialysis, Bari Policlinic Hospital</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pasquale Coratelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal, Dialysis and Transplant Unit, University of Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Corciulo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesco P Schena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephology and Dialysis Unit, &quot;Salvini&quot; Hospital</name>
      <address>
        <city>Bollate</city>
        <zip>20021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology, University of &quot;G. d'Annunzio&quot;</name>
      <address>
        <city>Chieti</city>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lorenzo Di Liberato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrologyand Dialysis Unit, Desio Hospital</name>
      <address>
        <city>Desio</city>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Renzo Scanziani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Pozzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;Maria SS dello Splendore&quot; Hospital</name>
      <address>
        <city>Giulianova</city>
        <zip>64021</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giancarlo Marinangeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;Renzetti&quot; Hospital</name>
      <address>
        <city>Lanciano</city>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Margherita Maccarone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology and Dialysis, Ospedale Policlinico Maggiore</name>
      <address>
        <city>Milano</city>
        <zip>20121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amedeo De Vecchi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Piergiorgio Messa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;G. Bernabeo&quot; Hospital</name>
      <address>
        <city>Ortona</city>
        <zip>66026</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Stingone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renal Unit, Policlinico MultiMedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvio V Bertoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;SS Annunziata&quot; Hospital</name>
      <address>
        <city>Sulmona</city>
        <zip>67039</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Cerasoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Nephrology and Dialysis, &quot;Mazzini&quot; Hospital</name>
      <address>
        <city>Teramo</city>
        <zip>64100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Goffredo Del Rosso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nephrology and Dialysis Unit, &quot;San Pio da Pietrelcina&quot; Hospital</name>
      <address>
        <city>Vasto</city>
        <zip>66054</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Di Paolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>September 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2008</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peritoneal dialysis</keyword>
  <keyword>L-carnitine</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Glucose homeostasis</keyword>
  <keyword>Dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

